Cost-utility of enoxaparin compared with unfractionated heparin in unstable coronary artery disease.

ABSTRACT:

Background

Low molecular weight heparins hold several advantages over unfractionated heparin including convenience of administration. Enoxaparin is one such heparin licensed in the UK for use in unstable coronary artery disease (unstable stable angina and non-Q wave myocardial infarction). In these patients, two large randomised controlled trials and their meta-analysis showed small benefits for enoxaparin over unfractionated heparin at 30-43 days and potentially at one year. We found no relevant published full economic evaluations, only cost studies, one of which was conducted in the UK. The other studies, from the US, Canada and France, are difficult to interpret since their resource use and costs may not reflect UK practice.

Methods

We aimed to compare the benefits and co

SUBMITTER: Nicholson T 

PROVIDER: S-EPMC59676 | biostudies-literature | 2001

REPOSITORIES: biostudies-literature